Thalamic Deep Brain Stimulation for Spasmodic Dysphonia- DEBUSSY Trial

Not Applicable

Completed

• Conditions: Laryngeal Dystonia; Deep Brain Stimulation; Spasmodic Dysphonia
• Interventions: Device: VIM Thalamic Deep Brain Stimulation ON; Device: VIM Thalamic Deep Brain Stimulation OFF

• Registration Number: NCT02558634
• Lead Sponsor: University of British Columbia

Brief Summary

Laryngeal Dystonia (LD), also commonly referred to as spasmodic dysphonia, is a neurological voice disorder characterized by involuntary dystonic contractions of the laryngeal muscles. Current treatments such as botox and voice therapy only provide temporary relief and thus, the investigators are exploring new strategies to provide long-term, sustained improvement.

Deep Brain Stimulation (DBS) is a neurosurgical procedure that involves the implantation of electrodes to deliver electrical stimuli to specific brain regions. It is the standard surgical treatment for many other movement disorders such as Parkinson's disease, essential tremor, and primary dystonia. This trial has been designed to test the hypothesis that DBS can improve the vocal dysfunction of LD.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2015-09-22
• Study First Submitted QC: 2015-09-23
• Study First Posted: 2015-09-24
• Study Start: 2016-01
• Primary Completion: 2019-05
• Study Completion: 2020-03
• Results First Submitted: 2020-10-26
• Results First Submitted QC: 2022-01-26
• Results First Posted: 2022-03-29
• Status Verified: 2022-05
• Last Update Submitted: 2022-05-20
• Last Update Posted: 2022-06-14

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 6

Inclusion Criteria

• Clinically diagnosed isolated laryngeal dystonia (adductor spasmodic dysphonia)
• Able to give informed consent
• Patients who fall into the age range of 18-75 years old
• Patients with inadequate medical and BTX management of spasmodic dysphonia

Read More

Exclusion Criteria

• Dystonia present in other body parts (i.e- eyes, neck, limbs) in addition to larynx
• History of laryngeal denervation surgery for spasmodic dysphonia
• History of intracranial pathology (such as multiple sclerosis, tumors, or aneurysms) that may account for dystonia or essential tremor.
• History or evidence of ongoing psychiatric or neurodegenerative disorders (such as Parkinson's disease, Alzheimer's disease).
• Incompetent adults or those unable to communicate.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
DBS-on	VIM Thalamic Deep Brain Stimulation ON	Ventral intermediate Nucleus (VIM) Thalamic DBS on DBS system includes: * Implantable Pulse Generator (IPG) * DBS Lead * DBS Lead Extension Kit
DBS-off (sham-stimulation)	VIM Thalamic Deep Brain Stimulation OFF	Ventral intermediate Nucleus (VIM) Thalamic DBS off DBS system includes: * Implantable Pulse Generator (IPG) * DBS Lead * DBS Lead Extension Kit

Primary Outcome Measures

Name	Time	Method
Unified Spasmodic Dysphonia Rating Scale (USDRS)	After the first 6 months, the participants completed the USDRS twice (once per crossover).	Assessments of spasmodic dysphonia using a standardized spasmodic dysphonia rating scale were done pre-operatively, blinded DBS ON, blinded DBS OFF, and open DBS ON. Voice recording taken of each patient reading standardized sentences were blinded and evaluated by two speech language pathologists. The scale ranges from 0-7, with lower scores being better and higher scores being worse.
Voice-Related Quality of Life	After the first 6 months, the participants completed the V-RQoL twice (once per crossover).	Double-blinded assessments of voice-related quality of life with DBS ON/OFF were conducted using the V-RQoL for Spasmodic Dysphonia. The V-RQoL is a questionnaire that measures a patient's voice related quality of life. The scale ranges from 0-50, with higher scores representing a lower quality of life with respect to voice.

Secondary Outcome Measures

Name	Time	Method
Beck's Depression Inventory Scale	All participants completed the BDI-II once pre-operatively and once 1 year post-operatively (after the 6-month open unblinded phase).	Beck's Depression Inventory Scale (BDI-II) was used in this study to evaluate the mood of the patients both pre-operatively and at the end of the one-year study.; All 6 patients completed the BDI-II, which is a scale that identifies symptoms and attitudes associated with depression, and evaluates the presence and severity of depression. The BDI-II ranges from 0-63. Scores ranging from 0-10 are considered to be absent or minimal depression, 10-18 indicate mild to moderate depression, 19-29 indicate moderate depression, and 30-63 indicate severe depression.
Montreal Cognitive Assessment Scale (MoCA)	All participants completed the MoCA once pre-operatively and once 1 year post-operatively (after the 6-month open unblinded phase).	The MoCA was used to analyze the cognitive ability of the patients. It was first evaluated pre-operatively and again evaluated at the end of the one-year study. The MoCA scale ranges from 0-30 with higher scores indicating less cognitive impairment. Scores ranging from 18-25 indicate mild cognitive impairment, 10-17 indicate moderate cognitive impairment, and scores less than 10 indicate severe cognitive impairment.
Voice-Handicap Index	All participants completed the VHI once pre-operatively and once 1 year post-operatively (after the 6-month open unblinded phase).	The Voice-Handicap Index (VHI) is a questionnaire that measures the patients' perceived degree of handicap related to their voice. The VHI ranges from a scale of 0-100, with higher scores reflecting higher perceived degree of voice handicap and lower scores reflecting lower perceived degree of voice handicap.

Trial Locations

Locations (1)

The Vancouver General Hospital; 🇨🇦 Vancouver, British Columbia, Canada